21/12/2020 - General information
The Codi Risc research project, coordinated by the IMIM Health Services research group and the Neuroscience research group from the Parc Taulí de Sabadell Hospital Consortium, is launching its new website and intranet. Codi Risc is a research project on the prevention of suicidal behaviour based on the Codi Risc Suïcidi (CRS) programme, which was created and implemented in Catalonia in 2014 by the Catalan Government's Department of Health. The purpose of the Codi Risc project is to study the frequency, as well as the epidemiological, clinical, neuropsychological, and biological risk factors involved in suicide attempts and repeated suicide attempts. It also covers the implementation, effectiveness, and costs of the Catalan Government's Codi Risc Suïcidi programme, as well as the development of personalised suicide risk prediction algorithms aimed at preventing suicidal behaviour.
Més informació "Codi RISC research project launches web and intranet"
03/08/2020 - General information
The Innovation Radar, a European Commission initiative to identify high potential innovations and innovators in EU-funded research and innovation framework programmes, has selected two innovations developed by the GRIB in the project eTRANSAFE to be included on the Innovation Radar platform: Preclinical text mining solution for treatment response Advanced in silico modelling to predict toxicity These innovations, stemming from the project work, have been classified by the Innovation Radar as Exploring innovations in the early phases of technological readiness and have been published on the EU-funded innovations website on July 20th 2020, thus joining the 3600+ EU-funded innovations already showcased on the platform.
28/07/2020 - General information
The main goal of the European project EHDEN: European Health Data & Evidence Network, is to carry out large-scale analysis of European clinical data (Real-World Clinical Data), using bioinformatics tools and standards based on the international OHDSI initiative and the OMOP common date model (CDM). EHDEN will speed up studies and research related to characterising patients with COVID-19 and other diseases, and evaluate the best treatments and clinical management for these patients, using millions of clinical records from all over Europe.
29/06/2020 - General information
This month Sifted, the technology magazine of the Financial Times, has contacted various experts in the technology industry and in analyzing data on investments, has concluded that the Spanish entrepreneurial ecosystem has high quality healthtech startups, ranging from drug discovery to novel virtual reality therapies. In its latest edition, Sifted has published a list of the top healthcare start-ups in Spain, including Chemotargets, the IMIM's spin-off founded in 2006 by Dr. Jordi Mestres, coordinator of the Systems Pharmacology research group at IMIM. Chemotargets is a company that offers state-of-the-art methodologies with predictive capabilities that allow the pharmaceutical and biotechnology industry to accelerate the design and optimization of drug candidates and improve cost efficiency and safety. Its CLARITY® platform covers the entire field of drug discovery and development, from the de novo design of molecules for new targets to pharmacovigilance in the drug market stage.
25/06/2020 - General information
Dr. Ferran Sanz, Dra. Laura Furlong and Dr. Baldo Oliva of the IMIM Biomedical Informatics Research Program, participate in the Disc4All project: Training network to advance integrated computational simulations in translational medicine, applied to intervertebral disc degeneration, coordinated by Jérôme Noailly, principal investigator in the Biomechanics and Mechanobiology research area at BCN MedTech of UPF. It is one of the ten selected projects in Catalonia as an Innovative Training Network (ITN) Marie Sklodowska-Curie, in the European Commission's ITN MSC Actions call. The European innovative training networks (ITN) aim to train a new generation of researchers in their early stages who are creative, enterprising and innovative, capable of dealing with the challenges of the future and turn knowledge and ideas into products and services with an economic and a social benefit.
18/05/2020 - General information
The GRIB Integrative Biomedical Informatics group (IMIM-UPF) has launched a new version of DisGeNET (version 7.0, May 8, 2020), which contains more than 1 million associations between 21,000 genes and 30,000 diseases, and 350,000 associations involving more than 190,000 genomic variants. All the data sources have been updated including the information automatically extracted by text mining of the literature. In addition, a new resource focused on COVID-19 has also been created. DisGeNET is a public knowledge management platform that offers information on genes and genomic variants associated with human diseases, which is obtained by integrating data from more than a dozen public resources and the scientific literature. DisGeNET contains one of the most comprehensive collections of genes and variants associated with human diseases that is currently available and is a resource for sharing and exchanging information recommended by the ELIXIR project, which is called, ELIXIR Recommended Interoperability Resource.
09/05/2019 - General information
The GRIB Integrative Biomedical Informatics group (IMIM-UPF) has launched a new version of DisGeNET, a public knowledge management platform on the genomics of disease, which is celebrating its tenth anniversary this year. DisGeNET offers information on genes and genomic variants associated with human diseases, which is obtained by integrating more than a dozen public resources and the scientific literature. DisGeNET contains one of the most comprehensive collections of genes and variants associated with human diseases that is currently available. The new version of DisGeNET (6.0) contains approximately 600,000 associations between more than 17,000 genes and 24,000 human diseases, focusing particularly on genetic alterations associated with disease: this version includes more than 117,000 genomic variants associated with 10,000 diseases. In addition, the phenotypic landscape covered by DisGeNET has been expanded to include the genomic basis of clinical manifestations of diseases, both signs and symptoms, as well as laboratory tests results.
Més informació "New version of DisGeNET 6.0 and ELIXIR recognition"
10/04/2019 - General information
The project EOSC-Life aims to create an open collaborative digital space for life science in the European Open Science Cloud (EOSC). EOSC-Life brings together the 13 european research infrastructures in the Health and Food domain of the ESFRI Roadmap and is funded by H2020 for the period 2019-2023. The project involves research groups from 46 European academic institutions. These include the GRIB Systems Pharmacology research group (IMIM-UPF) led by Jordi Mestres, which is helping develop collaborative tools for integrating and analysing all kinds of data in the field of life sciences.
07/06/2018 - General information
Sudden cardiac arrest (SCA) continues to be a major public health challenge, accounting for about 20% of all natural deaths in industrialised countries. Although there has been a substantial decline in overall coronary heart disease mortality rates in the past 30 years, SCA rates have fallen to a lesser extent. Some 50 % of all cardiovascular deaths are caused by SCA, a condition in which the heart suddenly and unexpectedly stops beating. With survival rates ranging between 5 % and 20 %, there's a need to improve SCA prevention and treatment. To address this issue, a European public-private consortium is now working on the creation of a joint, harmonised database by analysing SCA victims and DNA samples, along with detailed clinical and medication use information. unded by H2020 Programme of the European Union, the team of scientists contributing to the ESCAPE-NET project, including the System Pharmacology group of GRIB (IMIM-UPF) led by Jordi Mestres, summarised the objectives of their research in the 'European Heart Journal'.
15-01-2018 - General information
The Food and Drug Administration's Center for Drug Evaluation and Research (FDA/CDER) and Chemotargets will work together under a 5-year Research Collaboration Agreement (RCA). The primary objective of the research agreement will be to assess the utility and performance of the Chemotargets CLARITY® intelligence & discovery platform to predict on-target and off-target activities using known pharmacology and safety data from experimental studies of small molecular entities. Evaluating in silico models for broad pharmacological profiling is of interest to CDER to predict potential adverse events of drugs in development. Additionally, insight into a chemical’s molecular target profile can help predict abuse and addiction potential, which may reduce risks associated with exposure to these substances.
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
